首页 > 最新文献

Communicable diseases intelligence (2018)最新文献

英文 中文
Australian Gonococcal Surveillance Programme, 1 July to 30 September 2024. 澳大利亚淋球菌监测规划,2024年7月1日至9月30日。
Q3 Medicine Pub Date : 2025-03-25 DOI: 10.33321/cdi.2025.49.018
Monica M Lahra, Sebastiaan van Hal, Tiffany R Hogan

Abstract: The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 July to 30 September 2024.

摘要:澳大利亚国家奈瑟菌网络(NNN)由每个州和地区的参考实验室组成,这些实验室向澳大利亚淋球菌监测计划(AGSP)商定的抗微生物药物组报告抗微生物药物敏感性测试数据。AGSP数据每季度以表格形式公布一次,也在AGSP年度报告中公布一次。本报告介绍了2024年7月1日至9月30日国家淋球菌抗微生物药物耐药性监测数据。
{"title":"Australian Gonococcal Surveillance Programme, 1 July to 30 September 2024.","authors":"Monica M Lahra, Sebastiaan van Hal, Tiffany R Hogan","doi":"10.33321/cdi.2025.49.018","DOIUrl":"10.33321/cdi.2025.49.018","url":null,"abstract":"<p><strong>Abstract: </strong>The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 July to 30 September 2024.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cluster of Brucella melitensis in Melbourne, Australia 2023: clinical and public health actions. 2023年澳大利亚墨尔本的一例梅利氏布鲁氏菌聚集性病例:临床和公共卫生行动
Q3 Medicine Pub Date : 2025-03-25 DOI: 10.33321/cdi.2025.49.015
Manogna Metlapalli, Fiona Clarke, Anna B Pierce, Norelle L Sherry, Jake A Lacey, Edura Jalil, Aswan Tai, Christian McGrath, Tony Korman, James H McMahon, Rhonda L Stuart

Abstract: Brucellosis is a rare zoonotic infection most commonly seen in parts of the Northern Hemisphere. Infections in Australia are uncommon and occur predominantly in Queensland and New South Wales due to the association with wild pig hunting activities. We describe a clustering of two cases of brucellosis in Victoria confirmed by genomic analysis but with no identified exposure. We detail the medical management, laboratory confirmation, and the public health investigation. While the source of the outbreak remains unclear, the two cases demonstrate a detailed and coordinated public health response to a rare infection with a unique geographical and temporal relationship.

摘要:布鲁氏菌病是一种罕见的人畜共患感染,最常见于北半球部分地区。由于与野猪狩猎活动有关,澳大利亚的感染并不常见,主要发生在昆士兰州和新南威尔士州。我们描述了维多利亚州的两个聚集性布鲁氏菌病病例,经基因组分析证实,但没有确定的暴露。我们详细介绍了医疗管理、实验室确认和公共卫生调查。虽然疫情的来源仍不清楚,但这两个病例表明,对一种具有独特地理和时间关系的罕见感染采取了详细和协调的公共卫生应对措施。
{"title":"A cluster of Brucella melitensis in Melbourne, Australia 2023: clinical and public health actions.","authors":"Manogna Metlapalli, Fiona Clarke, Anna B Pierce, Norelle L Sherry, Jake A Lacey, Edura Jalil, Aswan Tai, Christian McGrath, Tony Korman, James H McMahon, Rhonda L Stuart","doi":"10.33321/cdi.2025.49.015","DOIUrl":"10.33321/cdi.2025.49.015","url":null,"abstract":"<p><strong>Abstract: </strong>Brucellosis is a rare zoonotic infection most commonly seen in parts of the Northern Hemisphere. Infections in Australia are uncommon and occur predominantly in Queensland and New South Wales due to the association with wild pig hunting activities. We describe a clustering of two cases of brucellosis in Victoria confirmed by genomic analysis but with no identified exposure. We detail the medical management, laboratory confirmation, and the public health investigation. While the source of the outbreak remains unclear, the two cases demonstrate a detailed and coordinated public health response to a rare infection with a unique geographical and temporal relationship.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian National Enterovirus Reference Laboratory annual report, 2023. 澳大利亚国家肠道病毒参考实验室年度报告,2023年。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.013
Matthew B Kaye, Linda K Hobday, Aishah Ibrahim, Leesa Brugink, Bruce R Thorley

Abstract: Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2023, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.71 non-polio AFP cases per 100,000 children, thereby meeting the WHO's performance criterion for a sensitive surveillance system. The non-polio enteroviruses coxsackievirus A9, coxsackievirus B5, echovirus 9, echovirus 30, enterovirus A71 and enterovirus C96 were identified from clinical specimens collected from AFP cases. Australia also performs enterovirus and wastewater surveillance to complement the clinical system focussed on children. In 2023, there were twelve cases of wild poliovirus reported from the last two remaining endemic countries: Afghanistan and Pakistan. Another 23 countries reported cases of poliomyelitis due to circulating vaccine-derived poliovirus.

摘要:澳大利亚按照世界卫生组织(WHO)的建议,通过对15岁以下儿童急性弛缓性麻痹(AFP)病例进行监测,监测其无脊髓灰质炎状况。儿童AFP病例通报给澳大利亚儿科监测单位或儿科主动强化疾病监测系统,并将粪便标本提交给国家肠道病毒参考实验室进行病毒学调查。2023年,临床监测中未报告脊髓灰质炎病例,澳大利亚报告每10万名儿童中有1.71例非脊髓灰质炎性AFP病例,从而达到世卫组织敏感监测系统的绩效标准。从AFP病例临床标本中检出非脊髓灰质炎肠道病毒柯萨奇病毒A9、柯萨奇病毒B5、埃可病毒9、埃可病毒30、肠病毒A71和肠病毒C96。澳大利亚还开展肠道病毒和废水监测,以补充以儿童为重点的临床系统。2023年,最后剩下的两个流行国家:阿富汗和巴基斯坦报告了12例野生脊髓灰质炎病毒病例。另有23个国家报告了由循环疫苗衍生的脊髓灰质炎病毒引起的脊髓灰质炎病例。
{"title":"Australian National Enterovirus Reference Laboratory annual report, 2023.","authors":"Matthew B Kaye, Linda K Hobday, Aishah Ibrahim, Leesa Brugink, Bruce R Thorley","doi":"10.33321/cdi.2025.49.013","DOIUrl":"10.33321/cdi.2025.49.013","url":null,"abstract":"<p><strong>Abstract: </strong>Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2023, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.71 non-polio AFP cases per 100,000 children, thereby meeting the WHO's performance criterion for a sensitive surveillance system. The non-polio enteroviruses coxsackievirus A9, coxsackievirus B5, echovirus 9, echovirus 30, enterovirus A71 and enterovirus C96 were identified from clinical specimens collected from AFP cases. Australia also performs enterovirus and wastewater surveillance to complement the clinical system focussed on children. In 2023, there were twelve cases of wild poliovirus reported from the last two remaining endemic countries: Afghanistan and Pakistan. Another 23 countries reported cases of poliomyelitis due to circulating vaccine-derived poliovirus.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2023. 澳大利亚抗微生物药物耐药性小组(琼脂)澳大利亚革兰氏阴性监测结果计划(GnSOP)血流感染年度报告2023。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.003
Jan M Bell, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, Geoffrey W Coombs

Abstract: The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2023 to 31 December 2023, a total of 57 hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). The 2023 survey tested 10,453 isolates, comprising Enterobacterales (9,503; 90.9%), P. aeruginosa (806; 7.7%) and Acinetobacter species (144; 1.4%), using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2024). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 12.9% of Escherichia coli and in 6.9% of Klebsiella pneumoniae complex isolates. Resistance rates to ciprofloxacin were 14.5% for E. coli; 7.8% for the K. pneumoniae complex; 3.2% for the Enterobacter cloacae complex; and 7.6% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 6.0%; 9.4%; 23.3%; and 13.7% for the same four species/complexes, respectively. Thirty Enterobacterales isolates from 30 patients were shown to harbour a carbapenemase gene: ten with a blaNDM gene (blaNDM-1 [4], blaNDM-5 [4], blaNDM-7 [2]); nine with a blaOXA-48-like gene (blaOXA-244 [4], blaOXA-48 [2], blaOXA-181 [1], blaOXA-232 [1], blaOXA-484 [1]); eight with blaIMP-4; two with blaNDM-5 + a blaOXA-181-like gene; and one with blaKPC-2 + blaNDM-5 + blaOXA-181. Transmissible carbapenemase genes were also detected in two Acinetobacter baumannii complex isolates (blaOXA-23; blaOXA-23 + blaOXA-58 + blaIMP-4) and one P. aeruginosa (blaIMP-4).

摘要:澳大利亚抗微生物药物耐药性小组(琼脂)进行定期流行研究,以监测选定的肠道革兰氏阴性病原体的抗微生物药物耐药性变化。从2023年1月1日至2023年12月31日,澳大利亚共有57家医院参加了澳大利亚革兰氏阴性监测结果方案(GnSOP)。2023年的调查检测了10453株分离物,包括肠杆菌(9503;90.9%),铜绿假单胞菌(806;7.7%)和不动杆菌(144种;1.4%),使用商业自动化方法。使用欧洲抗菌药物敏感性试验委员会(EUCAST)断点(2024年1月)对结果进行分析。据报告,在12.9%的大肠埃希菌和6.9%的肺炎克雷伯菌复合体分离株中,对第三代头孢菌素头孢曲松(ceftriaxone)具有主要耐药性。大肠杆菌对环丙沙星耐药率为14.5%;肺炎克雷伯菌复合体7.8%;阴沟肠杆菌复合体3.2%;铜绿假单胞菌为7.6%。哌拉西林-他唑巴坦耐药率为6.0%;9.4%;23.3%;对于相同的四种/配合物,分别为13.7%。从30例患者中分离的30株肠杆菌显示含有碳青霉烯酶基因:10株含有blaNDM基因(blaNDM-1 [4], blaNDM-5 [4], blaNDM-7 [2]);9个具有blaOXA-48样基因(blaOXA-244 [4], blaOXA-48 [2], blaOXA-181 [1], blaOXA-232 [1], blaOXA-484 [1]);8台blaIMP-4;2例携带blaNDM-5 + blaoxa -181样基因;一种是blaKPC-2 + blaNDM-5 + blaOXA-181。两株鲍曼不动杆菌复体分离株(blaOXA-23;blaOXA-23 + blaOXA-58 + blaIMP-4)和一个铜绿假单胞菌(blaIMP-4)。
{"title":"Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2023.","authors":"Jan M Bell, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, Geoffrey W Coombs","doi":"10.33321/cdi.2025.49.003","DOIUrl":"10.33321/cdi.2025.49.003","url":null,"abstract":"<p><strong>Abstract: </strong>The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2023 to 31 December 2023, a total of 57 hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). The 2023 survey tested 10,453 isolates, comprising <i>Enterobacterales</i> (9,503; 90.9%), <i>P. aeruginosa</i> (806; 7.7%) and <i>Acinetobacter</i> species (144; 1.4%), using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2024). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 12.9% of <i>Escherichia coli</i> and in 6.9% of <i>Klebsiella pneumoniae</i> complex isolates. Resistance rates to ciprofloxacin were 14.5% for <i>E. coli</i>; 7.8% for the <i>K. pneumoniae</i> complex; 3.2% for the <i>Enterobacter cloacae</i> complex; and 7.6% for <i>P. aeruginosa</i>. Resistance rates to piperacillin-tazobactam were 6.0%; 9.4%; 23.3%; and 13.7% for the same four species/complexes, respectively. Thirty <i>Enterobacterales</i> isolates from 30 patients were shown to harbour a carbapenemase gene: ten with a <i>bla</i><sub>NDM</sub> gene (<i>bla</i><sub>NDM-1</sub> [4], <i>bla</i><sub>NDM-5</sub> [4], <i>bla</i><sub>NDM-7</sub> [2]); nine with a <i>bla</i><sub>OXA-48</sub>-like gene (<i>bla</i><sub>OXA-244</sub> [4], <i>bla</i><sub>OXA-48</sub> [2], <i>bla</i><sub>OXA-181</sub> [1], <i>bla</i><sub>OXA-232</sub> [1], <i>bla</i><sub>OXA-484</sub> [1]); eight with <i>bla</i><sub>IMP-4</sub>; two with <i>bla</i><sub>NDM-5</sub> + a <i>bla</i><sub>OXA-181</sub>-like gene; and one with <i>bla</i><sub>KPC-2</sub> + <i>bla</i><sub>NDM-5</sub> + <i>bla</i><sub>OXA-181</sub>. Transmissible carbapenemase genes were also detected in two <i>Acinetobacter baumannii</i> complex isolates (<i>bla</i><sub>OXA-23</sub>; <i>bla</i><sub>OXA-23</sub> + <i>bla</i><sub>OXA-58</sub> + <i>bla</i><sub>IMP-4</sub>) and one <i>P. aeruginosa</i> (<i>bla</i><sub>IMP-4</sub>).</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An outbreak of Salmonella Muenchen gastroenteritis after consuming wild hunted kangaroo, Northern Territory, Australia, 2024. 2024年澳大利亚北部地区食用野生狩猎袋鼠后爆发的孟氏沙门氏菌肠胃炎。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.010
Anthony D K Draper, Joanne Gerrell, Stacey McKay, Janet Forrester, Ana Ordonez, Ella Meumann, Rob Baird, Dimitrios Menouhos, Manoj Basnet, Tinus Creeper, Max Cummins, Vicki Krause

Abstract: An outbreak of salmonellosis occurred in August 2024 after consuming wild hunted kangaroo in a remote area of the Northern Territory (NT), Australia. We conducted an outbreak investigation via telephone and face-to-face interviews, using a standardised questionnaire that recorded symptoms and exposures to foods and activities prior to onset of symptoms. A confirmed outbreak case was defined as anyone with laboratory confirmed Salmonella Muenchen infection who was part of a group of people who shared meals on 25-26 August 2024. A probable outbreak case was defined as anyone who was part of a group of people who shared meals on 25-26 August 2024 and subsequently experienced diarrhoea, in the absence of a laboratory test. Of the seven members of the group who shared meals, all became ill (attack rate 100%); three were confirmed cases and four were probable cases. The median age was 32 years (range 23-65 years); six (86%) were male. The median incubation period was 24 hours (range 6-30 hours). The most commonly reported symptoms were diarrhoea (100%, 7/7) and abdominal pain (86%, 6/7). Two cases were admitted to hospital, both for an overnight stay; all recovered. All seven cases consumed the same meal - a single, locally hunted and butchered kangaroo. Contamination likely occurred due to unsafe butchering, storage, transportation and insufficient cooking of the meat. This outbreak highlights the risks of contamination of game meat (in this case kangaroo) with Salmonella. Those preparing hunted meat should wash hands and knives regularly while butchering an animal to avoid contamination; should store butchered meat below 5 °C to avoid bacterial growth and cook foods thoroughly to kill microbes. We estimate that the cost to society of this outbreak was 9,810 Australian dollars.

摘要:澳大利亚北领地(NT)某偏远地区于2024年8月因食用野生狩猎袋鼠暴发沙门氏菌病。我们通过电话和面对面访谈进行了疫情调查,使用标准化问卷记录了症状和出现症状前的食物接触和活动情况。确诊暴发病例的定义是,2024年8月25日至26日与他人共餐的任何实验室确诊的慕尼黑沙门氏菌感染病例。2024年8月25日至26日与他人共餐并随后在没有实验室检测的情况下出现腹泻的人被定义为可能的暴发病例。在共进晚餐的7名成员中,所有人都生病了(发病率100%);3例为确诊病例,4例为可能病例。中位年龄32岁(23-65岁);6例(86%)为男性。中位潜伏期为24小时(范围6-30小时)。最常见的报告症状是腹泻(100%,7/7)和腹痛(86%,6/7)。两例患者入院,均住院过夜;所有的恢复。所有7个病例都吃了同样的食物——一只在当地猎杀并屠宰的袋鼠。污染可能是由于不安全的屠宰、储存、运输和不充分的肉类烹饪造成的。这次暴发突出了野味(在本例中为袋鼠)被沙门氏菌污染的风险。准备猎获肉的人在屠宰动物时应定期洗手和洗刀,以避免污染;应将屠宰后的肉类保存在5°C以下,以避免细菌滋生,并将食物彻底煮熟以杀死微生物。我们估计,这次疫情给社会造成的损失为9810澳元。
{"title":"An outbreak of Salmonella Muenchen gastroenteritis after consuming wild hunted kangaroo, Northern Territory, Australia, 2024.","authors":"Anthony D K Draper, Joanne Gerrell, Stacey McKay, Janet Forrester, Ana Ordonez, Ella Meumann, Rob Baird, Dimitrios Menouhos, Manoj Basnet, Tinus Creeper, Max Cummins, Vicki Krause","doi":"10.33321/cdi.2025.49.010","DOIUrl":"10.33321/cdi.2025.49.010","url":null,"abstract":"<p><strong>Abstract: </strong>An outbreak of salmonellosis occurred in August 2024 after consuming wild hunted kangaroo in a remote area of the Northern Territory (NT), Australia. We conducted an outbreak investigation via telephone and face-to-face interviews, using a standardised questionnaire that recorded symptoms and exposures to foods and activities prior to onset of symptoms. A confirmed outbreak case was defined as anyone with laboratory confirmed <i>Salmonella</i> Muenchen infection who was part of a group of people who shared meals on 25-26 August 2024. A probable outbreak case was defined as anyone who was part of a group of people who shared meals on 25-26 August 2024 and subsequently experienced diarrhoea, in the absence of a laboratory test. Of the seven members of the group who shared meals, all became ill (attack rate 100%); three were confirmed cases and four were probable cases. The median age was 32 years (range 23-65 years); six (86%) were male. The median incubation period was 24 hours (range 6-30 hours). The most commonly reported symptoms were diarrhoea (100%, 7/7) and abdominal pain (86%, 6/7). Two cases were admitted to hospital, both for an overnight stay; all recovered. All seven cases consumed the same meal - a single, locally hunted and butchered kangaroo. Contamination likely occurred due to unsafe butchering, storage, transportation and insufficient cooking of the meat. This outbreak highlights the risks of contamination of game meat (in this case kangaroo) with <i>Salmonella</i>. Those preparing hunted meat should wash hands and knives regularly while butchering an animal to avoid contamination; should store butchered meat below 5 °C to avoid bacterial growth and cook foods thoroughly to kill microbes. We estimate that the cost to society of this outbreak was 9,810 Australian dollars.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare urban-acquired human leptospirosis and environmental health investigation in Sydney, Australia. 澳大利亚悉尼罕见城市获得性人钩端螺旋体病及环境卫生调查。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.011
Mark J Ferson, Sinead Flanigan, Mark E Westman, Ana M Pastrana Velez, Benjamin Knobel, Toni Cains, Marianne Martinello

Abstract: Leptospirosis is a zoonosis caused by exposure to Leptospira excreted into the environment by rodents or other mammals. A notification of a case of leptospirosis in an adult male with no history of travel or exposure to livestock or rodents triggered an environmental health investigation of his workplace, a local golf course. We hypothesised that a water splash in the eye from a creek running through the golf course, which occurred after a period of heavy rainfall, had led to Leptospira exposure, likely on the basis of contamination of the creek water by rodent urine. Testing of environmental water samples detected pathogenic Leptospira DNA in ten of eleven samples, although cultures were negative. However, we had difficulty interpreting this finding as we found Leptospira DNA in ten of 14 environmental samples in inner and eastern Sydney remote from the workplace, and these were not associated with notified human cases. When we reviewed the 53 human leptospirosis cases notified over the twenty-year period 2003-2022 in residents of metropolitan Sydney, of the 49 cases with Leptospira exposure information, 46 had recognised sources of exposure: travel overseas (27) or to tropical northern Australia (5); rural exposure often to livestock and/or rodents (12); work in an abattoir (1); and involvement in a raspberry farm outbreak (1). Only three, including the case described, acquired infection in suburban Sydney. Acquisition of human leptospirosis is a rare event in suburban Sydney; true cases without a travel or occupational exposure history may be under-recognised by clinicians. However, with increasing biodiversity loss and where climate change results in heavier rainfall and more frequent floods, it is likely that human leptospirosis will become more common in urban as well as endemic settings.

摘要:钩端螺旋体病是一种由啮齿动物或其他哺乳动物暴露于排泄到环境中的钩端螺旋体引起的人畜共患病。一名没有旅行史或与牲畜或啮齿动物接触史的成年男性出现钩端螺旋体病病例,这一通报引发了对其工作场所(当地一个高尔夫球场)的环境卫生调查。我们假设,在一段时间的强降雨后,流经高尔夫球场的小溪溅起的水花导致了钩端螺旋体暴露,可能是基于啮齿动物尿液污染了小溪的水。对环境水样的测试在11个样品中的10个样品中检测到致病性钩端螺旋体DNA,尽管培养呈阴性。然而,我们很难解释这一发现,因为我们在悉尼内部和东部远离工作场所的14个环境样本中发现了10个钩端螺旋体DNA,而这些样本与已报告的人类病例无关。当我们回顾2003-2022年20年间悉尼大都会居民报告的53例人类钩端螺旋体病病例时,在49例有钩端螺旋体暴露信息的病例中,46例有公认的暴露源:海外旅行(27)或热带澳大利亚北部(5);农村地区经常接触牲畜和/或啮齿动物(12);在屠宰场工作(1);并参与了覆盆子农场的爆发(1)。在悉尼郊区,包括上述病例在内,只有3人感染。人类钩端螺旋体病在悉尼郊区是罕见的事件;没有旅行或职业暴露史的真实病例可能被临床医生低估。然而,随着生物多样性丧失的加剧以及气候变化导致更强的降雨和更频繁的洪水,人类钩端螺旋体病很可能在城市和流行环境中变得更加常见。
{"title":"Rare urban-acquired human leptospirosis and environmental health investigation in Sydney, Australia.","authors":"Mark J Ferson, Sinead Flanigan, Mark E Westman, Ana M Pastrana Velez, Benjamin Knobel, Toni Cains, Marianne Martinello","doi":"10.33321/cdi.2025.49.011","DOIUrl":"10.33321/cdi.2025.49.011","url":null,"abstract":"<p><strong>Abstract: </strong>Leptospirosis is a zoonosis caused by exposure to <i>Leptospira</i> excreted into the environment by rodents or other mammals. A notification of a case of leptospirosis in an adult male with no history of travel or exposure to livestock or rodents triggered an environmental health investigation of his workplace, a local golf course. We hypothesised that a water splash in the eye from a creek running through the golf course, which occurred after a period of heavy rainfall, had led to <i>Leptospira</i> exposure, likely on the basis of contamination of the creek water by rodent urine. Testing of environmental water samples detected pathogenic <i>Leptospira</i> DNA in ten of eleven samples, although cultures were negative. However, we had difficulty interpreting this finding as we found <i>Leptospira</i> DNA in ten of 14 environmental samples in inner and eastern Sydney remote from the workplace, and these were not associated with notified human cases. When we reviewed the 53 human leptospirosis cases notified over the twenty-year period 2003-2022 in residents of metropolitan Sydney, of the 49 cases with <i>Leptospira</i> exposure information, 46 had recognised sources of exposure: travel overseas (27) or to tropical northern Australia (5); rural exposure often to livestock and/or rodents (12); work in an abattoir (1); and involvement in a raspberry farm outbreak (1). Only three, including the case described, acquired infection in suburban Sydney. Acquisition of human leptospirosis is a rare event in suburban Sydney; true cases without a travel or occupational exposure history may be under-recognised by clinicians. However, with increasing biodiversity loss and where climate change results in heavier rainfall and more frequent floods, it is likely that human leptospirosis will become more common in urban as well as endemic settings.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2024. 澳大利亚脑膜炎球菌监测:报告期为2024年7月1日至9月30日。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.017
Monica M Lahra, Tiffany R Hogan

Abstract: The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known, and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

摘要:澳大利亚脑膜炎球菌监测计划(AMSP)的参考实验室报告了通过培养和分子技术的实验室检测确认的侵袭性脑膜炎球菌病(IMD)病例数。季度报告中的数据仅限于按司法管辖区和已知血清组描述IMD病例数,并在2024年扩大到包括头孢曲松、青霉素、环丙沙星和利福平的抗微生物药物耐药性数据。AMSP年度报告中载有对每个历年实验室确认的IMD的全面分析。
{"title":"Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2024.","authors":"Monica M Lahra, Tiffany R Hogan","doi":"10.33321/cdi.2025.49.017","DOIUrl":"10.33321/cdi.2025.49.017","url":null,"abstract":"<p><strong>Abstract: </strong>The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known, and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A delayed diagnosis of lymphatic filariasis in a returned traveller from the Philippines. 从菲律宾返回的旅行者淋巴丝虫病的延迟诊断。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.014
George P Drewett, Hedayat Pourhadi, Jordan Kahn, Shio Yen Tio, Craig Aboltins

Abstract: A 71-year-old Australian-born man with previous extended travel to the Philippines presented with bilateral lymphoedema, fevers and rigors. Examination of a nocturnal blood film revealed microfilariae of Wuchereria bancrofti, confirming a diagnosis of Bancroftian filariasis. This case highlights the challenges of diagnosing and managing lymphatic filariasis in non-endemic regions.

摘要:一名71岁澳大利亚出生的男子,此前曾长期前往菲律宾,表现为双侧淋巴水肿、发烧和僵硬。夜间血片检查显示班氏乌氏丝虫病微丝虫病,确认班氏丝虫病诊断。这一病例突出了在非流行地区诊断和管理淋巴丝虫病的挑战。
{"title":"A delayed diagnosis of lymphatic filariasis in a returned traveller from the Philippines.","authors":"George P Drewett, Hedayat Pourhadi, Jordan Kahn, Shio Yen Tio, Craig Aboltins","doi":"10.33321/cdi.2025.49.014","DOIUrl":"10.33321/cdi.2025.49.014","url":null,"abstract":"<p><strong>Abstract: </strong>A 71-year-old Australian-born man with previous extended travel to the Philippines presented with bilateral lymphoedema, fevers and rigors. Examination of a nocturnal blood film revealed microfilariae of <i>Wuchereria bancrofti</i>, confirming a diagnosis of Bancroftian filariasis. This case highlights the challenges of diagnosing and managing lymphatic filariasis in non-endemic regions.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Gonococcal Surveillance Programme Annual Report, 2023. 澳大利亚淋球菌监测计划年度报告,2023年。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.007
Monica M Lahra, Sebastiaan van Hal, Tiffany R Hogan

Abstract: The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae for more than 40 years. In 2023, a total of 10,105 isolates from patients in the public and private sectors, in all jurisdictions, were tested for in vitro antimicrobial susceptibility by standardised methods. Nationally, in 2023, the AGSP captured antimicrobial susceptibility data for 25% of all gonococcal infection notifications. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2023, of N. gonorrhoeae isolates tested, 0.22% (22/10,105) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration (MIC) value ≥ 0.125 mg/L. Resistance to azithromycin was reported in 4.5% of N. gonorrhoeae isolates, proportionally stable since 2019. There were 27 isolates (0.27%) with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Victoria (13), New South Wales (11), non-remote Western Australia (2) and Queensland (1). This is the highest number ever detected and reported in a twelve-month period by the AGSP. In 2023, penicillin resistance was found in 30.7% of gonococcal isolates, and ciprofloxacin resistance in 60.3%, although there was considerable variation by jurisdiction. In some remote settings, penicillin remains recommended as part of an empiric therapy strategy. However, in 2023, in remote Northern Territory, five penicillin-resistant isolates were reported; and in remote Western Australia, 14.1% of gonococcal isolates (10/71) were penicillin resistant. In addition, there were eight ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates have increased in remote Western Australia (16/71; 22.5%). This increase in penicillin-resistant Neisseria gonorrhoeae in the Northern Territory has effected a change in gonococcal treatment recommendations.

摘要:澳大利亚淋球菌监测项目(AGSP)对淋病奈瑟菌的耐药性进行了40多年的持续监测。2023年,通过标准化方法对来自所有司法管辖区公共和私营部门患者的10105株分离株进行了体外抗菌药物敏感性检测。在全国范围内,2023年,AGSP收集了所有淋球菌感染通报中25%的抗菌药物敏感性数据。对于大多数澳大利亚人来说,目前淋病的推荐治疗仍然是头孢曲松和阿奇霉素的双重治疗。2023年,检测的淋病奈瑟菌分离株中,0.22%(22/10,105)符合世卫组织头孢曲松降低药敏(DS)标准,即最低抑制浓度(MIC)≥0.125 mg/L。据报告,4.5%的淋病奈球菌分离株对阿奇霉素耐药,自2019年以来比例稳定。在澳大利亚,维多利亚州(13株)、新南威尔士州(11株)、非偏远的西澳大利亚州(2株)和昆士兰州(1株)报告了27株(0.27%)对阿奇霉素具有高水平耐药性(MIC值≥256 mg/L)。这是AGSP在12个月期间检测和报告的最高数量。2023年,30.7%的淋球菌分离株出现青霉素耐药,60.3%的淋球菌分离株出现环丙沙星耐药,但各辖区差异较大。在一些偏远地区,仍建议将青霉素作为经验性治疗策略的一部分。然而,在2023年,在偏远的北领地,报告了5个青霉素耐药分离株;在偏远的西澳大利亚州,14.1%的淋球菌分离株(10/71)对青霉素耐药。此外,北领地偏远地区报告了8株环丙沙星耐药菌株;西澳大利亚偏远地区环丙沙星耐药率有所上升(16/71;22.5%)。北领地耐青霉素淋病奈瑟菌的增加影响了淋球菌治疗建议的变化。
{"title":"Australian Gonococcal Surveillance Programme Annual Report, 2023.","authors":"Monica M Lahra, Sebastiaan van Hal, Tiffany R Hogan","doi":"10.33321/cdi.2025.49.007","DOIUrl":"10.33321/cdi.2025.49.007","url":null,"abstract":"<p><strong>Abstract: </strong>The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in <i>Neisseria gonorrhoeae</i> for more than 40 years. In 2023, a total of 10,105 isolates from patients in the public and private sectors, in all jurisdictions, were tested for <i>in vitro</i> antimicrobial susceptibility by standardised methods. Nationally, in 2023, the AGSP captured antimicrobial susceptibility data for 25% of all gonococcal infection notifications. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2023, of <i>N. gonorrhoeae</i> isolates tested, 0.22% (22/10,105) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration (MIC) value ≥ 0.125 mg/L. Resistance to azithromycin was reported in 4.5% of <i>N. gonorrhoeae</i> isolates, proportionally stable since 2019. There were 27 isolates (0.27%) with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Victoria (13), New South Wales (11), non-remote Western Australia (2) and Queensland (1). This is the highest number ever detected and reported in a twelve-month period by the AGSP. In 2023, penicillin resistance was found in 30.7% of gonococcal isolates, and ciprofloxacin resistance in 60.3%, although there was considerable variation by jurisdiction. In some remote settings, penicillin remains recommended as part of an empiric therapy strategy. However, in 2023, in remote Northern Territory, five penicillin-resistant isolates were reported; and in remote Western Australia, 14.1% of gonococcal isolates (10/71) were penicillin resistant. In addition, there were eight ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates have increased in remote Western Australia (16/71; 22.5%). This increase in penicillin-resistant <i>Neisseria gonorrhoeae</i> in the Northern Territory has effected a change in gonococcal treatment recommendations.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuberculosis workforce policy and development framework in Australia. 澳大利亚结核病劳动力政策和发展框架。
Q3 Medicine Pub Date : 2025-02-19 DOI: 10.33321/cdi.2025.49.009
Ellen Donnan

Abstract: This document provides guidelines for tuberculosis (TB) workforce policy and development in Australia, detailing the multidisciplinary nature of the TB workforce, the roles, required skills, and priorities within that workforce, and strategies for its development. Training and development responsibilities and roles of various bodies are also detailed: the National TB Advisory Committee; jurisdictional TB programs and their administrators; the Australian Centre for Disease Control; and sundry other national and international bodies.

摘要:本文件为澳大利亚结核病劳动力政策和发展提供了指导方针,详细介绍了结核病劳动力的多学科性质、角色、所需技能、劳动力中的优先事项以及发展战略。还详细说明了各机构的培训和发展责任和作用:国家结核病咨询委员会;管辖结核病项目及其管理者;澳大利亚疾病控制中心;以及其他各种国家和国际机构。
{"title":"Tuberculosis workforce policy and development framework in Australia.","authors":"Ellen Donnan","doi":"10.33321/cdi.2025.49.009","DOIUrl":"10.33321/cdi.2025.49.009","url":null,"abstract":"<p><strong>Abstract: </strong>This document provides guidelines for tuberculosis (TB) workforce policy and development in Australia, detailing the multidisciplinary nature of the TB workforce, the roles, required skills, and priorities within that workforce, and strategies for its development. Training and development responsibilities and roles of various bodies are also detailed: the National TB Advisory Committee; jurisdictional TB programs and their administrators; the Australian Centre for Disease Control; and sundry other national and international bodies.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Communicable diseases intelligence (2018)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1